• FirefoxUpgrade to the new Firefox »
  •  Dow Up1.70% Nasdaq Up1.74%

    Inovio Pharmaceuticals, Inc. (INO)

    -NasdaqGS
    9.00 Up 0.22(2.48%) 2:43PM EST - Nasdaq Real Time Price
    Add to Portfolio
    ProfileGet Profile for:
    Inovio Pharmaceuticals, Inc.
    Building 18
    Suite 400
    Blue Bell, PA 19422
    United States - Map
    Phone: 267-440-4200
    Fax: 267-440-4242
    Website: http://www.inovio.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:71

    Business Summary 

    Inovio Pharmaceuticals, Inc., together with its subsidiaries, discovers, develops, and develops synthetic vaccines and immune therapies focusing on cancers and infectious diseases. The company’s DNA-based SynCon technology designed to provide protection against known and new unmatched strains of pathogens, such as influenza. Its electroporation DNA delivery technology uses controlled electrical pulses to enhance cellular DNA vaccine uptake. The company’s clinical programs include HPV-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus, hepatitis B virus, HIV, and malaria vaccines. It is also advancing preclinical research for a seasonal/pandemic influenza vaccine, as well as other products. The company was formerly known as Inovio Biomedical Corporation and changed its name to Inovio Pharmaceuticals, Inc. in May 2010. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Blue Bell, Pennsylvania.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Inovio Pharmaceuticals, Inc.

    Corporate Governance 
    Inovio Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Dec 1, 2014 is 7. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 6; Compensation: 8.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Dr. J. Joseph Kim Ph.D., 45
    Chief Exec. Officer, Pres, Director and Member of Fin. Committee
    861.00K0.00
    Mr. Peter D. Kies , 51
    Chief Financial Officer and Principal Accounting Officer
    427.00K0.00
    Dr. Niranjan Y. Sardesai Ph.D., 46
    Chief Operating Officer
    418.00K0.00
    Dr. Mark L. Bagarazzi M.D., 53
    Chief Medical Officer
    422.00K0.00
    Mr. Bernie Hertel ,
    VP of Investor Relations and Communications
    N/AN/A
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders